Overview
Considerations for Antimicrobial Selection in Clostridioides difficile Infection
Live Virtual Symposium in Collaboration with MAD-ID
Registration is closed for this activity.
Did you know that C. difficile is still classified as an urgent threat by the Centers for Disease Control Prevention?
In this activity, Dr. Paul Feuerstadt and Dr. Kevin Garey will discuss community and healthcare-associated infections, recent updates to guidelines, and evidence-based selection of antimicrobial therapy for the treatment of initial infection and prevention of recurrence CDI. What happens if the patient returns with recurrence? Join us to find out as the faculty discuss a patient case highlighting the risks of recurrence and selection of therapy.
This activity is intended for Health-system pharmacists, ID pharmacists, and other clinicians who care for patients with initial and recurrent Clostridioides difficile infection.
Clostridioides difficile is associated with significant morbidity and mortality, increased healthcare costs, and hospital readmission rates. As such, the Centers for Disease Control and Prevention continues to classify C. difficile as an urgent threat given the great burden on patients and the healthcare system.
A changing epidemiology, new therapies, accumulating clinical trial, and real-world data have ushered in advances in the treatment of C. difficile, prompting to changes in guidelines recommendations for the selection of antimicrobial therapy. Pharmacists may not be familiar with advances and evolving changes in the selection and application of antimicrobial therapies for treating initial and recurrent C. difficile infection.
As a result of participating in this educational activity, clinicians should be able to:
- Discuss the selection of antimicrobials considerate of their impact on gut microbiota
- Interpret data on the role of antitoxins in the treatment of initial infection and prevention of recurrent C. difficile infection
- Assess available and updated clinical guidelines to ensure evidence-based therapeutic selection for treatment of initial infection and prevention of recurrent C. difficile infection
- Describe clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
11:30 am - Welcome & Introductions
11:35 am - 11:55 am C. difficile: A Continued Threat (Kevin W. Garey, PharmD, MS)
11:55 am - 12:15 pm The Evolution of Therapy for C. difficile: What’s the Evidence? (Paul Feuerstadt, MD, FACG, AGAF)
12:15 pm - 12:25 pm Panel discussion (Dr. Garey and Dr. Feuerstadt)
12:25 pm - 12:30 pm Questions and Answers (Dr. Garey and Dr. Feuerstadt)
This program is developed by ACHL in collaboration with MAD-ID.
This activity is supported by an educational grant from Merck & Co., Inc.
Required hardware and software
Operating Systems: Windows® 2000. Windows® XP, Windows Vista®; Mac OS® X
Operating Systems: Windows® 2000. Windows® XP, Windows Vista®; Mac OS® X
Browsers: Final release versions of Internet Explorer® 6.0 or above, (Windows only); Mozilla Firefox 2.0 or above (Windows and Mac); Safari™ 3.0 or above (Mac only)
PDF Reader: Acrobat® or similar software may be required to view and print PDF files
Screen Resolution: 800 x 600 minimum
Enabled Security Settings: Allow per session cookies
**These minimum requirements are subject to change.
To access this virtual symposium on October 11th, please visit: https://event.arraylive.com/activity_files/615386bd496cd/101121-VA-ACHL.html
Paul Feuerstadt, MD, FACG, AGAF
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Kevin W. Garey, PharmD, MS
Professor and Chair
University of Houston College of Pharmacy
Houston, TX
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Paul Feuerstadt, MD, FACG, AGAF
Consulting Agreements: Ferring Pharmaceuticals, Inc., Roche Diagnostics, SERES Therapeutics, Takeda Pharmaceuticals
Speakers' Bureau: Merck and Company
Kevin W. Garey, PharmD, MS
Sources of Funding for Research: Acurx Pharmaceuticals, Paratek Pharmaceuticals, Inc., Summit Pharmaceuticals International, Tetraphase Pharmaceuticals, Inc.
Consulting Agreements: Merck and Company, Summit Pharmaceuticals International
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches to treating C. difficile infection and reducing recurrent episodes
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Participants are required to participate in the virtual symposium and complete the posttest, and evaluation.
Participants will receive an automated certificate within two weeks following the conference. There is no fee to participate in the activity or for the generation of the certificate.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 160.
CPE credit will be submitted to CPE Monitor® on the first day of each month.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity has been approved for 1.0 contact hours.
ACPE Universal Activity Number: 0396-0000-21-051-L01-P
Activity Type(s): Application
